Market Overview

UPDATE: Dawson James Initiates Spectrum Pharmaceuticals at Market Outperform on Share Weakness

Share:
Related SPPI
Spectrum Pharma Reports Publication of Beleodaq Data Selected as Rapid Communication in JCO
Time To Buy Casi Pharma, HC Wainwright

Dawson James initiated coverage on Spectrum Pharmaceuticals (NASDAQ: SPPI) with a Market Outperform rating and a $15 price target.

Dawson James noted, "Spectrum is a mid-cap, oncology/hematology focused biotechnology company with a rich portfolio of marketed and development stage drugs. … Spectrum stock is currently trading at $11-12 range, and has dropped >37% from its 52- week high of $17.48. From a valuation standpoint, the shares trade at 2.1 times FY12 and 1.6 times FY13 revenues, and <6 and <4 times our FY12 and FY13 EPS estimates, levels more commonly associated with shares of manufacturers of generic drugs. We consider the recent weakness in stock an excellent buying opportunity for investors."

Spectrum Pharmaceuticals closed at $11.28 on Monday.

Latest Ratings for SPPI

DateFirmActionFromTo
Apr 2015FBR CapitalInitiates Coverage onOutperform
Mar 2015JefferiesMaintainsHold
Feb 2015Roth CapitalDowngradesBuy

View More Analyst Ratings for SPPI
View the Latest Analyst Ratings

Posted-In: Dawson JamesAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (SPPI)

Get Benzinga's Newsletters